OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
TLC-2716 produced up to 57% placebo-adjusted triglyceride reductions, over 50% reductions in remnant cholesterol, and improvements in liver fat after four weeks of treatment
OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today presented results from its Phase 2a proof-of-concept study of TLC-2716 in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction-associated steatotic liver disease (MASLD). The oral, liver-targeted LXR inverse agonist met its primary efficacy endpoint, producing rapid, substantial placebo-adjusted reductions in triglycerides of 57% and 46% at the 6 mg and 12 mg doses, respectively, after four weeks of treatment. Among patients with baseline triglycerides ≥500 mg/dL — the population at highest risk for acute pancreatitis — both doses produced consistent placebo-adjusted reductions of approximately 62%. TLC-2716 also reduced remnant cholesterol by over 50%, improved liver fat, and was generally well tolerated. Chief Medical Officer and Head of Development, Rob Myers, MD, presented study data at the Endocrine Society’s Annual Meeting (ENDO 2026) in Chicago, Ill.
